Nebivolol

also known as NEB · Bystolic (nebivolol) · Nebilet · Nebivolol is bystolic

Developed for: hypertensive disorder · essential hypertension · coronary microvascular disorder · type 2 diabetes mellitus · atrial fibrillation · diastolic heart failure · heart disorder · heart failure
+30 more
· myocardial infarction · atrial flutter · brain aneurysm · cardiomyopathy · chemotherapy-induced toxicity · coronary artery disorder · coronary artery intramyocardial course · coronary vasospasm · COVID-19 · diabetic polyneuropathy · HER2 positive breast carcinoma · intermediate coronary syndrome · ischemic stroke · left ventricular failure · Marfan syndrome · nonobstructive coronary artery disease · ocular hypertension · open-angle glaucoma · peripheral arterial disease · pulmonary hypertension · ST-elevation myocardial infarction · symptomatic heart failure · triglyceride deposit cardiomyovasculopathy · atherosclerosis · chronic obstructive pulmonary disease · cirrhosis of liver · congestive heart failure · erectile dysfunction · metabolic syndrome X · postmenopausal osteoporosis
Investigated by: Forest Laboratories · Mylan Bertek Pharmaceuticals · Weill Medical College of Cornell University · Korea University Anam Hospital · Menarini Group · University of California, San Diego
+98 more
· Vanderbilt University · Aalborg University Hospital · Aarhus University Hospital · Agenzia Italiana del Farmaco · Ain Shams University · Amager Hospital · American Heart Association · Aristotle University Of Thessaloniki · Assistance Publique - Hôpitaux de Paris · Association Française contre les Myopathies (AFM), Paris · Berlin-Chemie Menarini · Betaliq, Inc. · Bio-innova Co., Ltd · Bispebjerg Hospital · Bornholm Hospital · Chonbuk National University Hospital · Chonnam National University Hospital · Chosun University Hospital · Chungbuk National University Hospital · Chungnam National University Hospital · Clinical Hospital Center Zemun · Creighton University · Daewoong Pharmaceutical Co. LTD. · Dong-A University · East Coast Institute for Research · Erling Bjerregaard Pedersen · Ewha Womans University Seoul Hospital · Fondazione IRCCS Policlinico San Matteo di Pavia · Gentofte Hospital · Giulio Stefanini · Glostrup University Hospital, Copenhagen · Gyeongsang National University Hospital · Herlev Hospital · Holbaek Hospital · Hospital of Southern Jutland · Hospitalsenheden Midt · Hospitalsenheden Vest · Hvidovre University Hospital · Icahn School of Medicine at Mount Sinai · Inje University Ilsan Paik Hospital · Jack Rubinstein · Jagiellonian University · Jeju National University Hospital · Kangbuk Samsung Hospital · Keimyung University Dongsan Medical Center · Kyung Hee University Hospital · Lebanese American University Medical Center · Lidia Szczepaniak · Martin Huelsmann · Massachusetts General Hospital · Mayo Clinic · Merck Sharp & Dohme LLC · Mercy Research · Minneapolis Heart Institute Foundation · Mylan Laboratories · Naestved Hospital · National Cancer Institute, Egypt · National Center for Cardiovascular Research Carlos III · National Institute of General Medical Sciences (NIGMS) · National Institute on Aging (NIA) · National Taiwan University Hospital · Nordsjaellands Hospital · Nykoebing Hospital · Odense University Hospital · Presbyterian medical center · Regionshospitalet Horsens · Saint Vincent's Hospital, Korea · Samsung Changwon Hospital · Samsung Medical Center · Sejong General Hospital · Seoul National University Bundang Hospital · Silkeborg Sygehus · Slagelse Hospital · Spanish Society of Cardiology · all 104 on the full record

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansion	US (FDA)	BYSTOLIC	—	2010-02-19	fda.gov ↗
Approved	US (FDA)	BYSTOLIC	—	2007-12-17	fda.gov ↗

Trials 65 · started per year

today

US approved 2007

2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028202920302031

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT01358409	Apr 2011 → Feb 2013	triglyceride deposit cardiomyovasculopathy	Lidia Szczepaniak	Completed	No outcome recorded
Phase 14 trials
Phase 1	NCT06248099	Jul → Aug 2024	—	Bio-innova Co., Ltd	Unknown	No outcome recorded
Phase 1	NCT04888728	Jun → Jul 2021	idiopathic pulmonary fibrosis	Daewoong Pharmaceutical Co. LTD.	Completed	No outcome recorded
Phase 1	NCT00158093	Jun → Jul 2003	essential hypertension	Mylan Bertek Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT00223717	Jan 2001 → Jan 2017	hypertensive disorder	Vanderbilt University	Completed	No outcome recorded
Phase 25 trials · 1 missed
Phase 2	NCT07233499	Jan 2025 → Feb 2027 expected	HER2 positive breast carcinoma	Ain Shams University	Recruiting	No outcome recorded
Phase 2	NCT04910100	Apr 2021 → Mar 2022	ocular hypertension, open-angle glaucoma	Betaliq, Inc.	Completed	Missed primary
Phase 2	NCT03655964	Aug 2018 → Aug 2019	ischemic stroke	Aristotle University Of Thessaloniki	Completed	No outcome recorded
Phase 2	NCT01679652	Aug 2012 → Sep 2013	essential hypertension	Erling Bjerregaard Pedersen	Completed	No outcome recorded
Phase 2	NCT00200421	May 2002 → Aug 2003	hypertensive disorder	Mylan Bertek Pharmaceuticals	Completed	No outcome recorded
Phase 2/33 trials
Phase 2/3	NCT06201611	Nov 2024 → Dec 2025 overdue	diabetic polyneuropathy	St. John's Research Institute	Recruiting	No outcome recorded
Phase 2/3	NCT06424834	Oct 2024 → Dec 2026 expected	coronary artery intramyocardial course, coronary microvascular disorder, coronary vasospasm, intermediate coronary syndrome	Stanford University	Recruiting	No outcome recorded
Phase 2/3	NCT00829296	Jan 2009 → Apr 2012	hypertensive disorder, type 2 diabetes mellitus	University of Chicago	Completed	No outcome recorded
Phase 316 trials · 2 met primary
Phase 3	NCT06755801	Apr 2025 → Mar 2026 overdue	coronary microvascular disorder, nonobstructive coronary artery disease	Spanish Society of Cardiology	Not yet recruiting	No outcome recorded
Phase 3	NCT04631536	Jan 2021 → Mar 2022	COVID-19	Lebanese American University Medical Center	Unknown	No outcome recorded
Phase 3	NCT05728632	Jan 2019 → Feb 2023	breast cancer, chemotherapy-induced toxicity, diffuse large B-cell lymphoma, left ventricular failure	Giulio Stefanini	Unknown	No outcome recorded
Phase 3	NCT01648634	Feb 2012 → Jul 2021	Duchenne muscular dystrophy, cardiomyopathy, heart failure	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 3	NCT01508026	Jan 2012 → Mar 2013	hypertensive disorder	Forest Laboratories	Completed	Met primary
Phase 3	NCT01415505	Aug 2011 → Jan 2013	essential hypertension	Forest Laboratories	Completed	No outcome recorded
Phase 3	NCT01499134	Aug 2011 → Jun 2014	hypertensive disorder, peripheral arterial disease	Thomas Jefferson University	Completed	Met primary
Phase 3	NCT00683124	Jul 2008 → Jul 2013	Marfan syndrome	Fondazione IRCCS Policlinico San Matteo di Pavia	Unknown	No outcome recorded
Phase 3	NCT00547300	Oct 2007 → Jan 2008	hypertensive disorder	Forest Laboratories	Terminated	No outcome recorded
Phase 3	NCT00142584	Aug 2005 → Mar 2008	hypertensive disorder	Mylan Bertek Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00145210	Apr 2005 → Sep 2007	hypertensive disorder	Mylan Bertek Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00200434	Oct 2002 → Oct 2003	hypertensive disorder	Mylan Bertek Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00200499	Mar 2002 → Sep 2003	hypertensive disorder	Mylan Bertek Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00145236	Nov 2001 → Aug 2003	hypertensive disorder	Mylan Bertek Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00200460	Sep 2001 → Mar 2003	hypertensive disorder	Mylan Bertek Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00200473	Sep 2001 → Mar 2003	hypertensive disorder	Mylan Bertek Pharmaceuticals	Completed	No outcome recorded

Phase 427 trials · 4 met primary · 2 missed
Phase 4	NCT04432610	Jan → Dec 2030	—	Clinical Hospital Center Zemun	Withdrawn	No outcome recorded
Phase 4	NCT06249802	Jan 2025 → Jan 2029 expected	brain aneurysm	Jagiellonian University	Not yet recruiting	No outcome recorded
Phase 4	NCT06035978	Mar 2024 → Apr 2026	symptomatic heart failure	University Hospital Ostrava	Unknown	No outcome recorded
Phase 4	NCT05585125	Feb 2024 → Jul 2026 overdue	diastolic heart failure	Weill Medical College of Cornell University	Enrolling by invitation	No outcome recorded
Phase 4	NCT05019027	Jan 2024 → Mar 2026 overdue	amyloidosis, heart disorder	Weill Medical College of Cornell University	Enrolling by invitation	No outcome recorded
Phase 4	NCT04769362	May 2021 → Jan 2026 overdue	myocardial infarction	Samsung Medical Center	Recruiting	Met primary
Phase 4	NCT03778554	Dec 2018 → Apr 2025 overdue	ST-elevation myocardial infarction	Bispebjerg Hospital	Active not recruiting	Met primary
Phase 4	NCT03596385	Oct 2018 → Jan 2025	myocardial infarction	National Center for Cardiovascular Research Carlos III	Completed	Missed primary
Phase 4	NCT02817360	Feb 2016 → Dec 2025 overdue	heart disorder, type 2 diabetes mellitus	Martin Huelsmann	Recruiting	No outcome recorded
Phase 4	NCT03245996	Jun 2015 → Sep 2016	—	Tartu University Hospital	Completed	No outcome recorded
Phase 4	NCT02710071	Jan 2015 → Apr 2016	essential hypertension	University of California, San Diego	Completed	No outcome recorded
Phase 4	NCT02053246	Jan 2014 → Mar 2021	diastolic heart failure, pulmonary hypertension	University of Florida	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT01665508	Apr 2013 → May 2015	coronary microvascular disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT01771406	Feb 2013 → Feb 2016	hypertensive disorder, obstructive sleep apnea syndrome	Universitaire Ziekenhuizen KU Leuven	Unknown	No outcome recorded
Phase 4	NCT01605370	Jun 2012 → Mar 2013	hypertensive disorder	Mayo Clinic	Terminated	No outcome recorded
Phase 4	NCT01961323	Mar 2012 → Mar 2016	hypertensive disorder	Icahn School of Medicine at Mount Sinai	Completed	No outcome recorded
Phase 4	NCT01595516	Feb 2012 → Oct 2017	hypertensive disorder	University of Colorado, Boulder	Completed	No outcome recorded
Phase 4	NCT01415531	Aug 2011 → Mar 2012	essential hypertension	Forest Laboratories	Completed	Met primary
Phase 4	NCT00992056	Dec 2010 → Feb 2012	hypertensive disorder	University of Miami	Completed	No outcome recorded
Phase 4	NCT01218100	Oct 2010 → May 2011	hypertensive disorder	Forest Laboratories	Completed	No outcome recorded
Phase 4	NCT01206439	Sep 2010 → Aug 2012	hypertensive disorder	Jack Rubinstein	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT01202175	Jul 2010 → Jun 2012	hypertensive disorder	University of California, San Diego	Completed	No outcome recorded
Phase 4	NCT01057251	Mar → Dec 2010	hypertensive disorder	Forest Laboratories	Completed	Met primary
Phase 4	NCT00999102	Oct 2009 → Jan 2011	hypertensive disorder	Weill Medical College of Cornell University	Completed	Missed primary
Phase 4	NCT00893984	May 2009 → Jun 2012	coronary artery disorder	Minneapolis Heart Institute Foundation	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT00744237	Aug 2008 → Jul 2010	hypertensive disorder, type 2 diabetes mellitus	Forest Laboratories	Completed	No outcome recorded
Phase 4	NCT01248338	Mar 2006 → Dec 2008	hypertensive disorder	Berlin-Chemie Menarini	Completed	No outcome recorded

Phase not applicable9 trials · 1 met primary
—	NCT07123506	Sep 2025 → Nov 2028 expected	atrial fibrillation, atrial flutter, atrial septal defect	Yonsei University	Not yet recruiting	No outcome recorded
—	NCT04513509	Oct 2020 → Jun 2022	atrial fibrillation	National Taiwan University Hospital	Completed	No outcome recorded
—	NCT05328310	Jan 2019 → Dec 2022	hypertensive disorder	Korea University Anam Hospital	Unknown	No outcome recorded
—	NCT02619526	Dec 2016 → Jul 2018	heart failure	Dong-A University	Unknown	No outcome recorded
—	NCT01044693	Jan 2010 → Jul 2014	hypertensive disorder, pure autonomic failure	Vanderbilt University	Completed	Met primary
—	NCT01051947	Dec 2009 → May 2010	—	Creighton University	Withdrawn	No outcome recorded
—	NCT01056718	Nov 2009 → Nov 2013	hypertensive disorder	Mercy Research	Completed	No outcome recorded
—	NCT00995072	Oct 2009 → Apr 2013	hypertensive disorder, sexual disorder	East Coast Institute for Research	Completed	No outcome recorded
—	NCT00849810	Jan 2009 → Nov 2010	hypertensive disorder	University of Mississippi Medical Center	Terminated	No outcome recorded Stop: Enrollment
Comparator or background therapy45 trials
Phase 0	NCT02467400 Comparator	Jul 2015 → Oct 2017	postmenopausal osteoporosis	Mayo Clinic	Completed	No outcome recorded
Phase 2	NCT04130438 Comparator	Oct 2020 → Mar 2022	coronary artery intramyocardial course	Stanford University	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01522950 Comparator	May 2010 → Oct 2016	hypertensive disorder	University of Minnesota	Completed	No outcome recorded
Phase 2/3	NCT01939990 Comparator	Jan 2012 → Mar 2013	hypertensive disorder	University of Chicago	Withdrawn	No outcome recorded Stop: Business
Phase 3	NCT05170061 Comparator	Feb 2013 → Sep 2014	hypertensive disorder	State University of New York at Buffalo	Completed	No outcome recorded
Phase 3	NCT00648895 Comparator	Nov 2007 → Jul 2009	hypertensive disorder	Forest Laboratories	Completed	No outcome recorded
Phase 4	NCT07513883 Background	Mar 2026 → Sep 2028 expected	heart failure	Ziekenhuis Oost-Limburg	Recruiting	No outcome recorded
Phase 4	NCT07397481 Comparator	Mar 2024 → Mar 2025	cirrhosis of liver, hypertensive disorder	Kafrelsheikh University	Completed	No outcome recorded
Phase 4	NCT06104423 Comparator	Oct 2023 → Feb 2024	hypertensive disorder	Menarini International Operations Luxembourg SA	Completed	No outcome recorded
Phase 4	NCT05513937 Comparator	May → Nov 2022	hypertensive disorder	Menarini International Operations Luxembourg SA	Completed	No outcome recorded
Phase 4	NCT04845061 Comparator	Oct → Dec 2021	chronic obstructive pulmonary disease	Ain Shams University	Unknown	No outcome recorded
Phase 4	NCT05257148 Comparator	May → Dec 2021	hypertensive disorder	Menarini International Operations Luxembourg SA	Completed	No outcome recorded
Phase 4	NCT04757584 Comparator	Apr 2021 → Apr 2023	diastolic heart failure	Weill Medical College of Cornell University	Completed	No outcome recorded
Phase 4	NCT04767061 Comparator	Apr 2021 → Apr 2022	diastolic heart failure	Weill Medical College of Cornell University	Completed	No outcome recorded
Phase 4	NCT04575675 Background	May → Nov 2020	heart failure, hypotensive disorder	Cheng-Hsin General Hospital	Completed	No outcome recorded
Phase 4	NCT03930433 Comparator	Jan 2018 → Mar 2019	coronary vasospasm	Korea University Anam Hospital	Completed	No outcome recorded
Phase 4	NCT03180593 Comparator	Feb 2017 → Jan 2018	heart disorder, hypertensive disorder	Trinity Hypertension & Metabolic Research Institute	Completed	No outcome recorded
Phase 4	NCT02200822 Comparator	Jul 2014 → Feb 2019	heart failure	Hasselt University	Completed	No outcome recorded
Phase 4	NCT01885988 Comparator	Mar 2013 → Mar 2014	erectile dysfunction	Martin M. Miner, MD	Unknown	No outcome recorded
Phase 4	NCT01395329 Comparator	May 2011 → Nov 2016	hypertensive disorder	University of Colorado, Boulder	Completed	No outcome recorded
Phase 4	NCT02057328 Comparator	Dec 2010 → Jan 2015	hypertensive disorder	Aristotle University Of Thessaloniki	Unknown	No outcome recorded
Phase 4	NCT03635125 Comparator	Aug 2010 → May 2011	—	Trinity Hypertension & Metabolic Research Institute	Completed	No outcome recorded
Phase 4	NCT01501929 Comparator	Aug 2010 → Dec 2015	hypertensive disorder	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 4	NCT01157234 Comparator	Jul 2010 → Jul 2014	hypertensive disorder	University of Florida	Completed	No outcome recorded
Phase 4	NCT01230892 Comparator	Feb 2010 → Sep 2013	atherosclerosis	Emory University	Completed	No outcome recorded
Phase 4	NCT01920282 Comparator	Jan 2010 → Aug 2012	hypertensive disorder	Virginia Polytechnic Institute and State University	Completed	No outcome recorded
Phase 4	NCT01041287 Comparator	Dec 2009 → Dec 2013	hypertensive disorder	Emory University	Completed	No outcome recorded
Phase 4	NCT01049009 Comparator	Dec 2009 → Jun 2012	hypertensive disorder	Emory University	Completed	No outcome recorded
Phase 4	NCT01502787 Comparator	Apr 2009 → Jun 2013	hypertensive disorder	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 4	NCT00785512 Comparator	Nov 2008 → Aug 2009	hypertensive disorder	Forest Laboratories	Completed	No outcome recorded
Phase 4	NCT00775671 Comparator	Oct 2008 → Jun 2011	metabolic syndrome X	Vanderbilt University	Completed	No outcome recorded
Phase 4	NCT00770861 Comparator	Sep 2008 → Nov 2009	hypertensive disorder	Forest Laboratories	Completed	No outcome recorded
Phase 4	NCT00734630 Comparator	Aug 2008 → Mar 2010	essential hypertension	Forest Laboratories	Completed	No outcome recorded
Phase 4	NCT00673790 Comparator	May 2008 → Jul 2010	hypertensive disorder	Forest Laboratories	Completed	No outcome recorded
Phase 4	NCT00673075 Comparator	May 2008 → Sep 2009	coronary artery disorder, hypertensive disorder	Forest Laboratories	Completed	No outcome recorded
Phase 4	NCT00517725 Comparator	Jul 2007 → May 2010	congestive heart failure	Centro Cardiologico Monzino	Completed	No outcome recorded
Phase 4	NCT00924833 Comparator	May → Nov 2006	altitude sickness, heart failure	Istituto Auxologico Italiano	Completed	No outcome recorded
Phase 4	NCT00295542 Comparator	Mar 2000 → Apr 2009	hypertensive disorder	University of Vigo	Completed	No outcome recorded
—	NCT07568574 Background	Mar 2026 → May 2028 expected	—	Enhanced Emirates Limited	Enrolling by invitation	No outcome recorded
—	NCT01996085 Comparator	Jan 2013 → Jun 2016	hypertensive disorder	Military Institute od Medicine National Research Institute	Completed	No outcome recorded
—	NCT01441570 Comparator	Feb 2012 → Jul 2013	hypertensive disorder	Brigham and Women's Hospital	Terminated	No outcome recorded Stop: Enrollment
—	NCT01076140 Comparator	Feb 2010 → Jan 2011	hypertensive disorder	University of Mississippi Medical Center	Withdrawn	No outcome recorded Stop: Enrollment
—	NCT00999752 Comparator	Oct 2009 → Feb 2010	hypertensive disorder	InVasc Therapeutics, Inc.	Completed	No outcome recorded
—	NCT00878384 Comparator	Apr 2009 → Jun 2012	atrial fibrillation, heart failure	Royal Brompton & Harefield NHS Foundation Trust	Completed	No outcome recorded
—	NCT00125853 Comparator	Jul 2006 → Jan 2009	hypertensive disorder	Imperial College London	Completed	Missed primary

Press releases naming this drug 1 release

Date	Issuer	Release
2025-09-22	Menarini Group	Lusochimica S.p.A. (Menarini Group) awarded by the European Commission with the ‘STEP Seal’ award and EU funding for the SmartNEBI project, which makes the synthesis of nebivolol greener and more sustainable menarini.com ↗

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 114 sources stand behind the page.

Field	Value	Cited text
Known as	Nebivolol	“Randomisation will be stratified according to the type of AMI (ie, ST-segment-elevation MI or non-ST-segment-elevation MI), type of β-blocker (carvedilol, bisoprolol, nebivolol...” PMID 39645270 ↗ Aug 2024 109 “Other names: acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, metoprolol succinate, metoprolol tartrate, nadolol, nebivolol, propranolol,...” NCT05585125 ↗ “Other Names: * acebutolol * atenolol * betaxolol * bisoprolol * carvedilol * labetalol * metoprolol succinate * metoprolol tartrate * nadolol * nebivolol * penbutolol *...” NCT05019027 ↗ “The beta-blockers used in this study are extended-release beta-blockers, specifically bisoprolol or nebivolol.” NCT07123506 ↗ “betablocker therapy chosen might be any of the following: atenolol bisoprolol carvedilol metoprolol nebivolol” NCT03596385 ↗ “Nebivolol is a medication that has been recently approved by the FDA for the treatment of hypertension.” NCT01049009 ↗ “Cardio-selective beta-blocker, including carvedilol, bisoprolol, metoprolol or nebivolol” NCT04575675 ↗ “Study group: Nebivolol • Patients will start with a dose of 5 mg every 24 hours.” NCT06755801 ↗ “Beta blocker: carvedilol, metroprolol, bisoprolol or nebivolol” NCT07513883 ↗ “Nebivolol/Valsartan 5/80mg randomly assigned for 8 weeks” NCT03180593 ↗ “nebivolol: 10mg/d → 5 mg/d → 2,5 mg/d → 1,25 mg/d stop” NCT02200822 ↗ Show 99 more sources
Known as	Bystolic (nebivolol)	“Bystolic® (nebivolol)” NCT00785512 ↗
Known as	NEB	“This is a Phase IV, interventional, multicenter, open-label, multinational study with 2 study periods (a Run-in period of 4 weeks and an Assessment period of 12 weeks) to...” NCT06104423 ↗ 4 “The goal of this study was to assess whether nebivolol (NEB), a vasodilatory β(1)-selective blocker, is a safe and efficacious monotherapy for individuals with systolic stage...” PMID 23332366 ↗ Jan 2013 “Nebivolol (NEB) in contrast to atenolol (ATE) may have a beneficial effect on endothelial function and may be more effective than ATE in preventing CVD.” PMID 29184167 ↗ Nov 2017 “We compared an angiotensin receptor blocker (valsartan; VAL), a beta-blocker (nebivolol; NEB) and the combination of NEB/VAL” PMID 26116459 ↗ Mar 2015 “Nebivolol (NEB)” NCT00142584 ↗
Known as	Nebilet	“Nebivolol (Nebilet) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.” NCT06035978 ↗
Known as	Nebivolol is bystolic	“Nebivolol is bystolic” NCT00849810 ↗
Action	Inhibit	“The third-generation beta-adrenergic blocker nebivolol retains the beta-adrenergic blocker effects” PMID 19430350 ↗ Apr 2009
Modality	Other / unclassified	“The third generation beta-blocker, nebivolol, has vasodilating properties in addition to beta-adrenergic blockade.” NCT01499134 ↗
Route	Oral	“nebivolol administered orally once daily” NCT00200499 ↗